Clinical Trial Update: Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating GEN1046 as a single agent or in combination with pembrolizumab for recurrent/metastatic non-small cell lung cancer, with the study cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GEN1046
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Genmab | Conditions: Non Small Cell Lung Cancer Metastatic | Phase 2 | Status: ACTIVE_NOT_RECRUITING